As a result of this educational activity learners will demonstrate: 1. Increased knowledge of the guideline recommendations for frontline treatment of PTCL; 2. Improved knowledge of the clinical implications of CD30-directed therapy in frontline treatment of PTCL; and 3. Improved knowledge and competence in the use of frontline CD30-directed therapy for patients with PTCL to optimize outcomes. This microburst activity is targeted towards US-based hematologist/oncologists, oncologists (including community physicians), nurse practitioners (including oncology-focused NPs) and physician assistants.
- Provider:Answers in CME Inc. (AiCME)
- Activity Link: https://www.answersincme.com/BHU
- Start Date: 2024-11-08 06:00:00
- End Date: 2024-11-08 06:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 0.5 hours
- Commercial Support: Source: Pfizer (Any division) - Amount: 190483.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Competence, Learner Knowledge
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest